The British Association for Psychopharmacology (BAP) has updated its 2026 pharmacological management guidelines to classify vaping as a first-line treatment for tobacco dependence. Citing high-level clinical evidence, the BAP instructs healthcare professionals to offer electronic cigarettes alongside traditional nicotine replacement therapies (NRTs) and medications like varenicline, emphasizing that patients should not stop vaping until they are entirely safe from smoking relapse.
Clinical Nicotine Dosage Recommendations
To standardize prescribing practices for healthcare professionals, the BAP has established specific nicotine concentration guidelines based on a patient’s daily combustible cigarette consumption.
| Daily Cigarette Consumption | Recommended Nicotine Concentration | Clinical Guidance |
|---|---|---|
| Less than 10 cigarettes/day | 3 to 12 mg/ml | Standard vaping transition. |
| 10 to 20 cigarettes/day | 12 to 18 mg/ml | Standard vaping transition. |
| More than 20 cigarettes/day | 18 mg/ml+ (or combination therapy) | More frequent use or combined with a nicotine patch. |
Evidence-Based Efficacy Over Traditional NRTs
The British Association for Psychopharmacology, alongside the National Institute for Health and Care Excellence (NICE), is one of the most highly regarded medical societies in the United Kingdom. In its February 2026 update on addiction treatment, the BAP synthesized recent systematic reviews to confirm that vaping offers better effectiveness in achieving successful withdrawal compared to traditional nicotine replacement therapies.
This conclusion is supported by a Cochrane systematic review, which the BAP notes provides a “high level of evidence.” The guidelines specifically highlight the clinical utility of nicotine salts for “more efficient inhalation” and stress the importance of a variety of non-tobacco flavors, which actively facilitate the transition away from combustible cigarettes.
Risk Stratification of Nicotine Delivery
Aligning with the 2024 report from the Royal College of Physicians (RCP), the BAP classifies nicotine delivery into four distinct categories based on health risks and addictive potential:
- Combustible tobacco products: Cigarettes and cigars (Highest harm).
- Non-combustible tobacco products: Snus and chewing tobacco (Lower risk due to absent combustion).
- Heated tobacco products (HTPs): No combustion, but significant risk reduction benefits are not yet fully established.
- Tobacco-free and combustion-free products: Electronic cigarettes, oral pouches, and NRTs (Lowest harm profile).
Verdict: Managing Relapse
The BAP’s 2026 guidelines represent a definitive shift in addiction medicine, removing the stigma from vaping and positioning it as a primary medical intervention. Crucially, the BAP addresses the issue of smoking relapse—the primary hurdle in addiction recovery. The guidelines explicitly state that patients “should only be advised to stop vaping if they are convinced they will not relapse.” This confirms that long-term harm reduction via vaping is clinically preferable to the risk of returning to combustible tobacco.
FAQ
-
Is vaping recommended by doctors in the UK?
Yes, the British Association for Psychopharmacology (BAP) and NICE recommend vaping as a first-line treatment for smoking cessation, noting it is more effective than traditional nicotine patches or gum.
-
What nicotine strength should I vape to quit smoking?
According to BAP clinical guidelines, smokers of under 10 cigarettes a day should use 3-12 mg/ml, while those smoking 10-20 a day should use 12-18 mg/ml.
-
When should I stop vaping after quitting smoking?
The BAP advises that patients should only stop vaping when they are absolutely convinced they will not relapse back to combustible cigarettes.
